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Acute endovascular treatment (EVT) has become part of the usual care for appropriately selected patients with 
ischemic stroke caused by an occlusion in the proximal 
intracranial anterior circulation. However, the role of EVT 
for patients with more distal occlusions in the second-order 
branches (M2) of the middle cerebral artery (MCA) is less 
Background and Purpose—It is unclear whether endovascular treatment (EVT) is beneficial for patients with acute 
ischemic stroke with occlusion of the M2 segment of the middle cerebral artery. We aimed to compare functional 
outcomes, technical aspects, and complications of EVT between patients with acute ischemic stroke because of M2 and 
M1 occlusions in clinical practice. Furthermore, outcome and complications after EVT in dominant and nondominant 
caliber M2 division occlusions were studied.
Methods—Data were obtained from the MR CLEAN Registry (Multicenter Randomized Clinical Trial of Endovascular 
Treatment for Acute Ischemic Stroke in the Netherlands) which is an ongoing observational study in 16 Dutch centers 
performing EVT in the Netherlands. Functional outcome was measured with the modified Rankin Scale score at 90 
days. Neurological recovery (delta National Institutes of Health Stroke Scale), successful reperfusion rates (extended 
Thrombolysis in Cerebral Infarction ≥2B), and safety outcomes were also investigated. Associations between occlusion 
location and outcome were analyzed with ordinal logistic regression models, with adjustment for other prognostic factors.
Results—In total, 244 (24%) patients with an M2 and 759 (76%) patients with an M1 occlusion who underwent EVT were 
analyzed. Functional outcomes were not significantly different between patients with M2 versus M1 occlusions (adjusted 
common odds ratio, 1.24; 95% CI, 0.87–1.73). Occurrence of symptomatic intracerebral hemorrhage was also similar for 
M2 and M1 occlusions (6.6% versus 5.9%; P=0.84). Further analysis about dominance of an M2 branch was performed 
in 175 (72%) patients. Neurological recovery was comparable (mean delta National Institutes of Health Stroke Scale, 
−2±10 for dominant M2, −5±5 for nondominant M2, and −4±9 [P=0.24] for M1 occlusions). Furthermore, the effect of 
reperfusion status on functional outcome was comparable between occlusion divisions (common odds ratio, 1.27; 95% 
CI, 1.06–1.53 for dominant M2; common odds ratio, 1.32; 95% CI, 0.93–1.87 for nondominant M2; and common odds 
ratio, 1.35; 95% CI, 1.24–1.46 for M1 occlusions).
Conclusions—Outcomes and complication rates after EVT were similar in patients with M2 and M1 occlusions. Although 
based on observational data and a limited sample size, a similar association of reperfusion status with functional outcome 
for all subgroups provides no evidence that patients with either a dominant or a nondominant M2 occlusion should be 
routinely excluded from EVT.   (Stroke. 2019;50:419-427. DOI: 10.1161/STROKEAHA.118.023117.)
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certain given that this population was underrepresented in ran-
domized controlled trials.1–3
Considering the distal location, smaller diameter and 
thinner walls of the M2 arterial segment, an M2 occlusion 
may result in more challenging endovascular procedures and 
an increased risk of periprocedural complications.1 These 
drawbacks potentially counterbalance the benefit of reper-
fusion. Furthermore, intravenous thrombolysis alone is more 
effective for recanalizing M2 occlusions relative to more 
proximal occlusions and therefore might limit the additional 
benefit of EVT.4,5
A recent meta-analysis reported that patients with M2 
occlusions achieved similar reperfusion and mortality rates 
as patients with M1 occlusions.6 Although symptomatic 
intracerebral hemorrhages were observed more frequently 
with M2 occlusions, rates of functional independence were 
higher among patients with an M2 occlusion. A lower base-
line National Institutes of Health Stroke Scale (NIHSS) score 
in M2 occlusion compared with M1 occlusion patients might 
explain this observation.6
The wide anatomic variation about the branching pattern 
of the MCA strongly influences the arterial territory at risk 
in case of an M2 occlusion. Several MCA branching patterns 
have been described in the anatomic and neuroradiological 
literature.7,8 The most important variation is in the blood sup-
ply to the parietal lobe, which can be fed by the inferior or 
superior M2 division or both. The M2 division that supplies 
the majority of the parietal lobe has a larger caliber, the dom-
inant M2 division. In some patients, a dominant M2 division 
can even approximate the diameter of the M1 segment. Owing 
to their larger territory at risk, dominant M2 occlusions typ-
ically lead to worse clinical outcomes than nondominant M2 
occlusions.3,8
Previous studies of the effect of EVT in patients with is-
chemic stroke did not distinguish between occlusion of dom-
inant and nondominant M2 divisions. It is probable that an 
occlusion of a dominant M2 may yield similar outcomes and 
treatment benefit as an M1 occlusion, whereas nondominant 
M2 branch occlusions may have a better natural history and 
reduced treatment effect.
Current stroke guidelines concluded that it may be rea-
sonable to treat patients experiencing an M2 occlusion with 
EVT, but further evidence is warranted.9 The aim of this study 
is to investigate 3-month functional outcome and the technical 
and safety aspects of EVT in patients with ischemic stroke 
because of M2 versus M1 occlusions. In addition, differences 
in outcome between dominant and nondominant M2 division 
occlusions are studied.
Methods
Data were obtained from the MR CLEAN Registry (Multicenter 
Randomized Clinical Trial of Endovascular Treatment for Acute 
Ischemic Stroke in the Netherlands), which is an ongoing prospective 
observational study in all centers performing EVT in the Netherlands. 
Detailed study design and methods have been described previously.10 
The MR CLEAN Registry was approved by the ethics committee 
of the Erasmus MC, Rotterdam, the Netherlands (MEC-2014-235). 
With this approval, it was approved by the research board of each 
participating center. At University Medical Center, approval to par-
ticipate in the study has been obtained from their own research board 
and ethics committee. Source data are not be made available because 
of legislative issues on patient privacy, but detailed analytic methods 
and study materials, including log files of statistical analyses, will 
be made available to other researchers on request (email: mrclean@
erasmusmc.nl).
Patients
All patients aged 18 years and older with a clinical diagnosis of acute 
ischemic stroke because of a proximal arterial occlusion in the ante-
rior circulation demonstrated by computed tomography angiography 
(CTA) and in whom EVT was initiated (defined as arterial puncture) 
within 6.5 hours after stroke onset were studied.10 For the present 
study, only patients with a documented M1 or M2 target occlusion 
on baseline digital subtraction angiography (DSA) were included. 
EVT consisted of mechanical thrombectomy or aspiration whether 
or not combined with arterial delivery of a thrombolytic agent. 
Method of EVT was left to the discretion of the interventionist. 
Patients included in this analysis were treated between March 16, 
2014, and June 15, 2016.
Image Analysis
Noncontrast CT, CTA, and DSA were scored by a core laboratory, 
except for the anatomic classification of the M2 branch which was 
assessed by 1 experienced neurointerventionist (A.C.G.M. van Es). 
Imaging analyses were performed blinded to clinical characteristics 
and outcomes. Alberta Stroke Program Early CT Score was meas-
ured on baseline noncontrast CT, collateral score on baseline CTA, 
and both occlusion segment, and extended Thrombolysis in Cerebral 
Infarction score was measured on DSA.11–13 DSA-only procedures 
were cases in which the target occlusion resolved or migrated too 
distally (M3 or M4 branches) caused by contrast flushing or manipu-
lation with the catheter, without actual performing of intended EVT.
In accordance with previously used definitions, the M1 segment 
and M2 branches were defined as follows on DSA: the M1 (horizontal 
or sphenoidal) segment extends from the bifurcation of the internal 
carotid artery below the anterior perforated substance to the limen 
insulae.1 At the limen insulae, the M1 makes a posterosuperior turn 
(genu) into the insula. The anterior temporal artery is identified as the 
artery that supplies the anterior temporal pole regardless of its size 
and whether it continues into the Sylvian fissure. All anatomic varia-
tions of the anterior temporal branch are considered M1 branches in 
this study. The M2 branches are considered those branches that are 
distal to the main bifurcation at the distal end of the horizontal M1 
segment. M2 branches extend from the posterosuperior turn (genu) of 
M1 to the circular sulcus of the insula.
For the purpose of this study, caliber dominance was considered 
present if 1 M2 branch had a larger diameter than the other on DSA 
or if the perfusion defect associated with the occluded M2 branch was 
larger than 50% of MCA territory (Figure 1). Only when the diam-
eters of both the inferior and superior branches were equal and the 
associated perfusion defect was ≈50% of MCA territory, the branches 
were considered codominant.
Outcomes
Primary outcome was functional outcome assessed with the mod-
ified Rankin Scale score at 90 days ranging from 0 (no symptoms 
or disability) to 6 (death).14 Secondary outcomes were functional 
independence (modified Rankin Scale score of 0–2), stroke se-
verity, and change in stroke severity. Stroke severity was measured 
using the NIHSS which ranges from 0 to 42 points (higher score 
indicating a more severe stroke). Follow-up NIHSS was assessed 
at 24 to 48 hours after treatment. Missing follow-up NIHSS scores 
in patients who died within 48 hours were assigned 42 points. 
Change in stroke severity was assessed with delta-NIHSS which 
was calculated as the absolute difference between baseline and fol-
low-up NIHSS: a negative value indicates a neurological improve-
ment, whereas a positive value indicates a neurological decline. 
Evaluation of technical aspects included post-EVT reperfusion 
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status (extended Thrombolysis in Cerebral Infarction score), pro-
cedural duration, number of stent retriever passes, and procedural 
complications (defined as vasospasm, vessel dissection or perfora-
tion, presence of distal thrombi, and new clots in a different vascular 
territory). Complete DSA runs including anteroposterior and lateral 
views were required to reach an extended Thrombolysis in Cerebral 
Infarction score of 2B or higher. A missing lateral view resulted in 
a maximum possible score of 2A. Successful reperfusion was con-
sidered when extended Thrombolysis in Cerebral Infarction 2B or 
higher was achieved. Safety aspects included symptomatic intracra-
nial hemorrhage15 and stroke progression (defined as a neurological 
deterioration by at least 4 points on the NIHSS).
Statistical Analyses
Patients who underwent EVT for acute ischemic stroke be-
cause of an M2 occlusion were compared with those treated 
with an M1 occlusion. Baseline characteristics of both patient 
groups were compared by means of the Wilcoxon rank-sum test 
or Student t test where appropriate and a χ2 test for categorical 
variables.
The difference in functional outcome between M2 and M1 
occlusions was expressed as a common odds ratio obtained from 
multivariable ordinal logistic regression.16 Adjustments were made 
for age, sex, NIHSS at baseline, time from stroke onset to groin 
puncture, intravenous thrombolysis, prestroke modified Rankin 
Scale, and CTA collateral status. For regression analysis, missing 
values were imputed by multiple imputations.17 To compare the 
association between functional outcome and reperfusion grade in 
each subgroup of occluded division, unadjusted ordinal logistic re-
gression was performed. Unadjusted and adjusted common odds 
ratios were reported with 95% CI. All analyses were performed 
with R (version 3.4.2) and packages rms, ggplot2, Hmisc, readxl, 
tableone, and haven. Probability values of <0.05 were considered 
significant for all tests.
Results
Baseline Patient Characteristics
Of the 1003 included patients, 244 (24%) patients had an M2 
occlusion and 759 (76%) had an M1 occlusion (Figure I in 
the online-only Data Supplement). No significant differences 
were observed between patients with M2 and M1 occlusions 
regarding age, sex and clinical risk factors for ischemic stroke, 
collateral grading score and time from stroke onset to groin 
puncture (Table 1). Compared with patients with M1 occlu-
sions, those with M2 occlusions had significantly lower me-
dian NIHSS scores (14 versus 16; P<0.001), higher ASPECT 
scores (median, 9; interquartile range [IQR], 8–10 versus me-
dian, 9; IQR, 7–10; P=0.01), and greater intravenous throm-
bolysis treatment (83% versus 76%; P=0.03). DSA-only 
procedures because of reperfusion before EVT occurred more 
often in the M2 occlusion group (12% versus 2%; P<0.001).
In 69 patients (28%) with an M2 occlusion, dominance 
of the M2 branch could not be reliably assessed because of 
poor quality or insufficient DSA imaging. This left 175 (72%) 
patients for further analysis. Dominance of either superior 
or inferior division was observed in 137 (78%) patients, and 
codominance of M2 branches was observed in 38 (22%) 
patients with M2 occlusion. Dominance of a branch was 
equally often observed in the superior or inferior division 
(respectively, 49% versus 51%; P>0.99). In patients with a 
dominant M2 branch, the occlusion was located in the domi-
nant division in 124 of the cases and in 51 of the cases in the 
nondominant branch. Baseline NIHSS was lower in patients 
Figure 1. Case example of a dominant M2 
superior division on digital subtraction angiog-
raphy (DSA). Arrows indicate the superior M2 
division. Asterisks indicate the inferior M2 divi-
sion. A, Anteroposterior view on DSA pre-endo-
vascular treatment (EVT), where a large part of 
the parietal lobe not perfused. B, Lateral view 
on DSA pre-EVT. C, Anteroposterior view on 
DSA after EVT. The parietal lobe is reperfused. 
D, Lateral view on DSA after EVT.
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with a dominant M2 occlusion than in patients with an M1 
occlusion (median, 14; IQR, 9–17 versus median, 16; IQR, 
12–20; P<0.001; Table I in the online-only Data Supplement).
Patients with an occlusion in a co- or nondominant divi-
sion had a lower NIHSS at baseline than patients with an M1 
occlusion (median, 14; IQR, 9–17 versus median, 16; IQR, 
12–20; P=0.002), and they had more DSA-only procedures 
(25% versus 2%; P<0.001; Table I in the online-only Data 
Supplement).
Outcomes
There was no significant difference in functional outcome 
between patients with an M2 occlusion and patients with an 
M1 occlusion (adjusted common odds ratio, 1.24; 95% CI, 
0.92–1.68; Figure 2). Likewise, the proportion of patients 
who achieved functional independence (modified Rankin 
Scale score of 0–2) at follow-up did not differ (101 [46%] for 
M2 occlusions versus 270 [39%]; P=0.10). Patients with an 
M2 occlusion had lower follow-up NIHSS scores (median, 8; 
IQR, 3–16 versus median, 11; IQR, 4–18; P=0.01). However, 
the difference in delta-NIHSS between the groups was not sta-
tistically significant (mean [SD], −3±9 versus −4±9; P=0.49; 
Table 2).
Successful reperfusion was similar in patients with M2 
or M1 occlusion (454 [60%] versus 135 [57%]; P=0.33), 
although duration of procedure was shorter in patients with 
an M2 occlusion (median, 50 minutes; IQR, 36–83 minutes 
versus median, 65 minutes; IQR, 41–90 minutes). There were 
no significant differences about procedural complications or 
symptomatic intracranial hemorrhage in both groups (28% 
versus 30%; P=0.64).
In patients with dominant M2 occlusions, EVT resulted 
in a similar functional outcomes compared with M1 
occlusions (adjusted common odds ratio, 1.19; 95% CI, 
0.79–1.80) and the proportion of patients with functional 
independence was not significantly different (42 [39%] 
versus 270 [39%]; P>0.99; Figure II in the online-only Data 
Supplement). Compared with M1 occlusions, the propor-
tion of functional independence stratified by reperfusion 
grade was similar to patients with a dominant M2 branch 
(Table 3). In addition, NIHSS at follow-up and delta-NIHSS 
did not differ, and technical and safety aspects were either 
equivalent or favorable in patients with a dominant M2 divi-
sion occlusion (Table 4).
Patients with co- or nondominant division occlusions of 
the M2 branch had better functional outcomes than patients 
with an M1 occlusion (adjusted common odds ratio, 2.22; 95% 
CI, 1.27–3.87; Figure III in the online-only Data Supplement). 
Also, patients with a co- or nondominant M2 branch occlusion 
became functionally independent more often than patients 
with an M1 occlusion (29 [59%] versus 270 [39%]; P<0.01). 
NIHSS at follow-up was lower in the co- or nondominant di-
vision occlusions, but delta-NIHSS was equal between both 
groups. Safety aspects did not differ between both groups 
(Table 4).
Discussion
In this study, we found that patients with ischemic stroke be-
cause of an M2 occlusion had similar functional outcomes com-
pared with stroke patients with an M1 occlusion. In addition, 
about neurological recovery (delta-NIHSS), no significant dif-
ferences were observed between both groups. Furthermore, no 
significant differences in occurrence of symptomatic intrace-
rebral hemorrhage or other safety aspects were observed. The 
majority of the M2 occlusions in our study were occlusions 
of a caliber dominant M2 branch. These occlusions may be 
often responsible for perfusion of the main part of the MCA 
territory.18 This can explain the similarity in clinical outcome 
between M1 and M2 occlusions. Furthermore, the association 
of reperfusion with functional outcome was similar between 
M1 and caliber dominant M2 occlusions. Compared with 
Table 1. Baseline Characteristics of Analyzed Patients
 
M2 Occlusion 
(n=244)
M1 Occlusion 
(n=759) P Value
Age (y) median [IQR] 72 [62–79] 70 [60–79] 0.48
Sex (male) (%) 128 (53) 404 (53) 0.89
Smoking (%) 55 (29) 186 (33) 0.39
Diabetes mellitus (%) 39 (16) 138 (18) 0.48
Atrial fibrillation (%) 50 (21) 176 (24) 0.40
Hypertension (%) 128 (53) 386 (52) 0.71
Previous myocardial infarction (%) 41 (17) 122 (17) 0.89
Previous stroke (%) 38 (16) 143 (19) 0.30
Hypercholesterolemia (%) 65 (28 239 (33) 0.22
Collateral grading score*   0.89
  0 15 (7) 39 (6)
  1 75 (33) 223 (32)
  2 91 (40) 288 (41)
  3 46 (20) 153 (21.8)
NIHSS score, median [IQR]† 14 [9–18] 16 [12–20] <0.001
ASPECTS, median [IQR]‡ 9 [8–10] 9 [7–10] 0.01
Prestroke modified Rankin Scale 
0–2 (%)§
221 (88) 657 (88) >0.999
Treatment with IV thrombolysis (%) 203 (83) 575 (76) 0.03
Time onset to groin (min), median 
[IQR]
200  
[152–274]
210  
[160–260]
0.60
DSA only (%)‖ 28 (12) 12 (2) <0.001
ASPECTS indicates Alberta Stroke Program Early CT Score; CTA, computed 
tomography angiography; DSA, digital subtraction angiography; IQR, interquartile 
range; IV, intravenous; and NIHSS, National Institutes of Health Stroke Scale.
*Assessed at baseline CTA. A score of 0 indicated absent collateral supply 
to the occluded territory, 1: filling of >0% but ≤50%, 2: filling of >50% but 
<100%, and 3: filling of 100% collateral supply of the occluded territory.
†National Institutes of Health Stroke Scale (scores range from 0 to 42, higher 
scores indicating severe stroke).
‡Alberta Stroke Program Early CT Score (scores range from 0 to 10 lower 
scores indicating more early ischemic changes on baseline noncontrast 
computed tomography).
§Functional disability before stroke onset, score ≤2 indicates functional 
independence.
‖Digital subtraction angiography without thrombectomy or aspiration, 
indicating spontaneous reperfusion.
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these occlusions, patients with occlusions of the nondominant 
M2 branch had better functional outcomes, likely owing to the 
smaller territory at risk and hence better natural history.
In accordance with a recent meta-analysis, we observed sim-
ilar clinical outcomes in patients with M2 and M1 occlusions.6 
Interestingly, we found lower complication rates which might 
be explained by advances in endovascular devices and increas-
ing experience of neurointerventionists. Similar to previous 
studies, we also found that NIHSS scores at baseline were 
lower in patients with M2 occlusions than in patients with M1 
Figure 2. Modified Rankin Scale (mRS) scores at 90 days: M1 vs M2 occlusion. Functional outcomes were statically significant difference between patients 
with M2 and M1 occlusions (common odds ratio, 1.40; 95% CI, 1.07–1.83). However, after adjustment for age, sex, National Institutes of Health Stroke Scale 
(NIHSS) baseline, time from stroke onset to groin puncture, intravenous thrombolysis (IVT), prestroke mRS, and collateral status, functional outcome was no 
longer statistically different (adjusted common odds ratio, 1.24; 95% CI, 0.92–1.68).
Table 2. Clinical, Technical, and Safety Outcomes in Patients With an M2 Occlusion on DSA Compared With 
Patients With an M1 Occlusion
 
M2 
(n=244)
M1 
(n=759) P Value
Clinical
  mRS score at 90 days, median [IQR]* 3 [1–5] 3 [2–6] 0.02
  mRS score 0–2 at 90 days (%) 101 (46) 270 (39) 0.10
  NIHSS follow-up (24–48 h), median [IQR] 8 [3–16] 11 [4–18] 0.01
  Delta-NIHSS, mean (SD)† −3 (9) −4 (9) 0.49
Technical
  Successful reperfusion (%)‡ 135 (57) 454 (60) 0.33
  Duration procedure, min, median [IQR] 50 [36–83] 65 [41–90] 0.01
  Total stent passes, median [IQR] 1 [0–2] 2 [1–3] <0.001
  Procedural complications on DSA (%) 57 (28) 213 (29.5) 0.64
  Vasospasm (%) 13 (6) 56 (8) 0.57
   Vessel dissection (%) 1 (1) 21 (3) 0.08
   Vessel perforation (%) 5 (2) 9 (1) 0.37
   Distal thrombus present (%) 30 (15) 104 (14) >0.999
   New thrombus different vascular territory (%) 10 (5) 35 (5) >0.999
Safety
  Symptomatic intracranial hemorrhage (%)§ 16 (7) 45 (6) 0.84
  Progression of the stroke (%)‖ 18 (7) 66 (9) 0.61
  Mortality at 90 days (%) 54 (22) 188 (25) 0.45
DSA indicates digital subtraction angiography; IQR, interquartile range; mRS, modified Rankin Scale; and NIHSS, 
National Institutes of Health Stroke Scale.
*Modified Rankin scale score was assessed at 90 days after stroke onset.
†Absolute difference between baseline NIHSS and follow-up NIHSS.
‡Extended Thrombolysis in Cerebral Infarction ≥2B, score of 0 indicates no perfusion or anterograde flow 
beyond occlusion site, 1: penetration of contrast but not perfusion, 2A: some perfusion <50% of vascular territory, 
2B: substantial perfusion ≥50%, 2C: almost complete perfusion 90%–99%, and 3: complete perfusion of vascular 
territory.
§Clinical deterioration because of intracranial hemorrhage defined by the Heidelberg bleeding classification.
‖Neurological deterioration by at least 4 points on the NIHSS.
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occlusions, indicating that M2 occlusion strokes are on average 
less severe.1,19 A previous population-based study showed that 
M2 occlusions were as often located in the superior as in the 
inferior division.20 However, other studies reported no differ-
ences in NIHSS scores at baseline which might be explained 
by differences in M2 segment definition, patient selection, or 
Table 4. Clinical, Technical, and Safety Outcomes in Patients With an M1, or Dominant M2 Division, or Co- or Nondominant M2 Division 
Occlusion
 
M1 Occlusion 
(n=759)
Dominant M2 
Division Occlusion 
(n=124)
Co- or 
Nondominant M2 
Division Occlusion 
(n=51) P Value
Functional
  mRS score at 90 days, median [IQR]* 3 [2–6] 3 [2–5] 2 [1–3] 0.01
  NIHSS follow-up (24–48 h), median [IQR] 11 [4–18] 11 [3–17] 6 [3–13] 0.03
  Delta-NIHSS, mean (SD)† −4 (9) −2 (10) −5 (5) 0.24
Technical
  Successful reperfusion (%)‡ 454 (60) 71 (57) 35 (71) 0.22
  Duration procedure, min, median [IQR] 65 [41–90] 56 [35–85] 52 [34–69] 0.01
  Total stent passes, median [IQR] 2 [1–3] 1 [1–2] 1 [0–2] <0.001
  Procedural complications (%) 213 (30) 29 (26) 11 (28) 0.73
   Vasospasm (%) 56 (8) 7 (6) 2 (5) 0.73
   Vessel dissection (%) 21 (3) 0 0 0.11
   Vessel perforation (%) 9 (1) 4 (4) 0 0.12
   Distal thrombus present (%) 104 (14) 14 (13) 6 (15) 0.85
   New thrombus different vascular territory, n (%) 35 (5) 5 (5) 3 (8) 0.71
Safety
  Symptomatic intracranial hemorrhage (%)§ 45 (6) 9 (7) 1 (2) 0.40
  Progression of the stroke (%)‖ 66 (9) 11 (9) 1 (2) 0.24
  Mortality at 90 days (%) 188 (25) 27 (22) 7 (14) 0.13
DSA indicates digital subtraction angiography; IQR, interquartile range; mRS, modified Rankin Scale; and NIHSS, National Institutes of 
Health Stroke Scale.
*Modified Rankin scale score was assessed at 90 days after stroke onset.
†Absolute difference between baseline NIHSS and follow-up NIHSS.
‡Extended Thrombolysis in Cerebral Infarction ≥2B, score of 0 indicates no perfusion or anterograde flow beyond occlusion site, 1: 
penetration of contrast but not perfusion, 2A: some perfusion <50% of vascular territory, 2B: substantial perfusion ≥50%, 2C: almost 
complete perfusion 90%–99%, and 3: complete perfusion of vascular territory.
§Clinical deterioration because of intracranial hemorrhage defined by the Heidelberg bleeding classification.
‖Neurological deterioration by at least 4 points on the NIHSS.
Table 3. Proportions of Functional Independence Stratified by Reperfusion Grades *
eTICI Score†
M1 (n=759) Dominant M2 (n=124) Co- or Nondominant M2 (n=51)
n (%) mRS Score of 0–2 (%) n (%) mRS Score of 0–2 (%) n (%) mRS Score of 0–2 (%)
0–1 117 (16) 10 (2) 35 (28) 8 (7) 6 (12%) 3 (6%)
2a 182 (24) 59 (9) 18 (15) 6 (6) 8 (16%) 5 (10%)
2b-3 454 (60) 199 (29) 71 (57) 28 (26) 35 (71%) 20 (41%)
cOR (95% CI)‡ 1.35 (1.24–1.46) 1.27 (1.06–1.53) 1.32 (0.93–1.87)
cOR indicates common odds ratio; DSA, digital subtraction angiography; eTICI, extended Thrombolysis in Cerebral Infarction; and mRS, modified 
Rankin Scale.
*eTICI scores were missing for 6 patients with an M1 occlusion on DSA and missing for 2 patients with a co- or nondominant M2 occlusion 
on DSA.
†eTICI score of 0 indicates no perfusion or anterograde flow beyond occlusion site, 1: penetration of contrast but not perfusion, 2A: some 
perfusion <50% of vascular territory, 2B: substantial perfusion ≥50%, 2C: almost complete perfusion 90%–99%, and 3: complete perfusion of 
vascular territory.
‡Complete scales of mRS score (dependent variable) and eTICI (independent) were used in the ordinal regression models.
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both.3 Furthermore, as in our study, no differences in technical 
and safety aspects between M2 and M1 occlusion segments 
were observed in previous studies.18,21 Distal occlusions can 
still cause functional dependence, indicating that reperfusion of 
small brain regions is important, as they may involve eloquent 
areas.22,23 A recent study of 212 patients compared outcomes 
after thrombectomy for M1 or M2 occlusions. Dominancy of 
caliber was not taken into account.24 M2 occlusions were more 
often located in the superior branch. However, occlusion in a 
specific branch was not a predictor for clinical outcome.
Limitations
This study has several limitations beyond the common limita-
tions of an observational study. First, we used DSA to identify 
thrombus location, although decision making in clinical prac-
tice is based on CTA findings. Therefore, results cannot be di-
rectly generalized to clinical decision making in the emergency 
room. Our objective was to assess technical and safety aspects 
of EVT in patients with an M2 occlusion.25 Second, ischemic 
stroke patients with a large-vessel occlusion who did not un-
dergo EVT are not registered in the MR CLEAN Registry. 
Therefore, patients with distal M2 occlusions may have 
been excluded, which could have resulted in selection bias. 
Nevertheless, patients with prestroke functional dependence, 
poor collateral grading scores, and poor vascular status were 
not excluded from the MR CLEAN Registry, and our results 
represent current routine practice. Third, anatomic variation of 
the M2 division branching pattern could not be assessed in all 
patients because of insufficient imaging of M2 branches in our 
retrospective analysis. Although we did not use advanced im-
aging such as perfusion scans to determine dominance, the ana-
tomic distribution of dominant M2 branches as was described 
in the present study is in line with previously published ana-
tomic studies. Also, our simple definition of dominant division 
observation during intervention on DSA makes it applicable 
during interventional procedures. However, adequate imaging 
of M2 branches is important in these patients from our experi-
ence. Fourth, in line with our third limitation, the precision of 
our estimates is limited, and results must be interpreted with 
care. Fifth, our study was based on an observational multi-
center registry. Although covariable-adjusted regression analy-
ses were performed, there might still be residual confounding 
in our study. Finally, follow-up imaging was not required in 
our registry, which precludes the analysis of infarct volume and 
asymptomatic hemorrhage as a secondary outcome.
In conclusion, outcomes and complication rates after EVT 
were similar in patients with M2 and M1 occlusions. Although 
based on observational data and a limited sample size, a sim-
ilar association of reperfusion status with functional outcome 
for all subgroups provides no evidence that patients with ei-
ther a dominant or nondominant M2 occlusion should be rou-
tinely excluded from EVT.
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